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It has been implied that the collagen binding integrin α11β1 plays a role in carcinogenesis.
As still relatively little is known about how the stromal integrin α11β1 affects different
aspects of tumor development, we wanted to examine the direct effects on primary tumor
growth, fibrosis, tumor interstitial fluid pressure (PIF) and metastasis in murine 4T1 mam-
mary and RM11 prostate tumors, using an in vivo SCID integrin α11-deficient mouse model.
Methods
Tumor growth was measured using a caliper, PIF by the wick-in-needle technique, activated
fibroblasts by α-SMA immunofluorescence staining and fibrosis by transmission electron
microscopy and picrosirius-red staining. Metastases were evaluated using hematoxylin and
eosin stained sections.
Results
RM11 tumor growth was significantly reduced in the SCID integrin α11-deficient (α11-KO)
compared to in SCID integrin α11 wild type (WT) mice, whereas there was no similar effect
in the 4T1 tumor model. The 4T1 model demonstrated an alteration in collagen fibril diame-
ter in the integrin α11-KO mice compared to WT, which was not found in the RM11 model.
There were no significant differences in the amount of activated fibroblasts, total collagen
content, collagen organization or PIF in the tumors in integrin α11-deficient mice compared
to WTmice. There was also no difference in lung metastases between the two groups.
Conclusion
Deficiency of stromal integrin α11β1 showed different effects on tumor growth and collagen
fibril diameter depending on tumor type, but no effect on tumor PIF or development of lung
metastasis.
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Introduction
Carcinomas consist of both malignant cells and stroma, the latter being composed of extracel-
lular matrix (ECM) molecules and associated cells [1]. The main focus of cancer research has
traditionally been on tumor cell alterations, but in the last decade ECM has been identified as
an important contributor to tumor development and progression [2, 3]. Tumor cells release
growth factors and proteolytic enzymes that modulate the stroma [4, 5], and the stromal com-
ponents interact with the tumor cells in a reciprocal manner to regulate different aspects of
tumor development [1].
Integrins belong to a family of major cell surface receptors that mainly bind ECM proteins.
Twenty-four different integrins, forming heterodimers by combining 18 α- and 8 β-subunits,
have been identified. The integrins mediate cell-cell and cell-matrix adhesion and are capable
of cell inside-out and outside-in signaling [6, 7]. Their role on the surface of tumor cells has
been extensively studied, and integrins contribute to proliferation, migration and survival of
malignant cells, and have thus been suggested to play an important role in tumor progression
[8]. Altered integrin expression in several stromal cells, including the cancer associated fibro-
blasts, may also influence tumor growth and progression [8–10], and the present study focuses
on the effect of the collagen binding integrin α11β1 in the tumor stroma.
The integrin subunit α11 forms a heterodimer with integrin subunit β1 and is one of four
collagen-binding integrins [11]. In mouse embryos, integrin α11β1 is a major collagen receptor
on a subset of fibroblasts [12], but characterization of its expression in adult and human tissue
is still insufficient [13]. Integrin α11β1 has high affinity for collagen type I, and has been indi-
cated to be involved in cell migration and collagen reorganization [10, 14, 15], but other than
this, there is limited knowledge about α11β1’s normal physiological role.
Integrin α11 has also been implicated to play a role in carcinogenesis. Integrin α11 is
expressed in metastases from human malignant melanoma [16], and in stromal fibroblasts in
human non-small-cell lung cancer (NSCLC) [9, 17]. It has also been shown, both in vitro and
in vivo, that α11 integrin expressed on fibroblasts may stimulate the growth of tumor cells [9,
10, 18]. Earlier findings have indicated that stromal integrin α11 has a role in both primary
tumor growth and in the metastatic process [9, 10], and this has raised the question if integrin
α11 could be used as a biomarker, or if targeting integrin α11 could prove to be a novel
approach in cancer treatment.
Since still relatively little is known about how the stromal integrin α11β1 in tumors affects
different aspects of tumor development, we decided to examine the direct effects of integrin
α11β1 on primary tumor growth, fibrosis, tumor interstitial fluid pressure and metastasis in a
4T1 mammary tumor- and a RM11 prostate tumor model.
Methods
Cell Lines
The murine mammary carcinoma cell line 4T1 was obtained from the American Type Culture
Collection (Manassas, VA., USA). The prostate cell line RM11 was a gift from Associate profes-
sor Thomas S. Griffith (University of Minnesota, Minneapolis, MN., USA). This cell line was
originally derived from a ras/myc reconstituted tumor in a Balb/c mouse [19]. The cells were
grown in RPMI-1640 medium (HEPES solution for RM11 cells) supplemented with 10% Foetal
Bovine Serum (Sigma-Aldrich, Steinheim, Germany), 100 units/ml penicillin, 100 μg/ml strep-
tomycin, 1–2% L-glutamine (all from Sigma-Aldrich, Steinheim, Germany), with an addition
of 1% sodium pyruvate for the RM11 cells. All cells were grown as single monolayers in a
humidified incubator at 37°C in 5% CO2 and they were seeded and used at log phase in all
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experiments. SV40 transformed wild type MEF cell line [12] was cultured in DMEM (Sigma-
Aldrich, Steinheim, Germany), 10% Foetal Bovine Serum and 100 units/ml penicillin, 100 μg/
ml streptomycin as previosly described.
Animal Model
The integrin α11-deficient heterozygous SCID mouse strain was generated as described [10].
The mice were bred heterozygously, and SCID integrin α11 wild type (WT) and SCID integrin
α11-deficient (α11-KO) offsprings were used in the experiments. PCR-genotyping was per-
formed on DNA extracted from ear biopsies as previously described [20]. Female mice were
used for the mammary 4T1 tumor model and male mice for the prostate RM11 tumor model.
The animals were kept in individually ventilated cages and cared for regularly. Efforts were
made to age- and weight match the animals. The animal experiments were approved by the
local ethical committee at The Laboratory Animal Facility, the Department of Clinical Medi-
cine, the Faculty of Medicine and Dentistry, University of Bergen (Permit Number 20135571).
All experiments were performed in accordance with the regulations of the Norwegian Animal
Research Authority.
Establishing Tumors
A total of 1 x 106 4T1 tumor cells in 0.15 ml PBS were injected into the fourth mammary fat
pads on each side. 3 x 105 RM11 cells were injected subcutaneously on both sides of the mouse
flank. The 4T1 tumors were measured using a caliper on days 7, 10, 13, 16 and endpoint 18
post injection, but some were ended day 17 due to rapid tumor growth. The RM11 tumors
were measured using a caliper on days 9, 11 and endpoint day 13 post injection. All experi-
ments were performed blinded to genotype. The tumor volume was calculated using the for-
mula; tumor volume (mm3) = (π/6) x a2 x b, where a represents the shortest diameter and b
represents the longest diameter of the tumor. All animals were anesthetized using Isofluran
(Isoba1vet. 100%, Schering-Plough A/S, Farum, Denmark) and were sacrificed by cervical dis-
location under anesthesia.
Measurement of Interstitial Fluid Pressure
The tumor interstitial fluid pressure (PIF) was measured using the wick-in-needle technique
[21]. Briefly, a standard 23-gauge needle with a side hole filled with nylon floss and saline was
inserted into the central part of the tumor after calibration and connected to a PE-50 catheter,
a pressure transducer and a computer for pressure registrations, using the software Powerlab
chart (version 5, PowerLAb/ssp ADinstruments, Dunedin, New Zealand). After a period of sta-
ble pressure measurements, the fluid communication was tested by clamping the catheter
which shall cause a transient rise and fall in pressure. Measurements were accepted if the pre-
to post-clamping value was within ± 1 mmHg.
Electron Microscopy of Collagen Fibrils in the Tumor
A JEM-1230 Transmission Electron Microscope (TEM) (Jeol, Tokyo, Japan) was used to mea-
sure the diameter of the collagen fibrils. The tissue samples were cut into approximately 1x1x1
mm samples and fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer, and then washed in
PBS. The samples were post-fixed in 1% OsO4 in PBS and dehydrated in increasing concentra-
tions of ethanol (70%, 95% and 100%), and then propylenoxide, before being embedded in
Agar 100 Resin and sectioned at 60 nm. Four to five images from different areas of the tissue
were captured at x100 000 magnification and analyzed using Image J 1.46 (National Institute
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of Health, Beteshda, MD., USA). Because of uneven distribution of collagen in the tissue, the
images were taken from the areas of the tissue where collagen was found.
A Jeol JSM-7400F Scanning Electron microscope (SEM) was used to study the tumor colla-
gen scaffold architecture. The tumors were cut in 1x1x1 mm samples and fixed in 2.5% glutar-
aldehyde in 0.1 M phosphate buffer, before being placed in 10% NaOH for 7 days with
replacement every day. The samples were thereafter placed in tap-water for 2–4 days and then
dehydrated in increasing concentrations of ethanol (70%, 95% and 100%), and dried in a “criti-
cal point-dryer”. The tumor tissue was mounted on an Au-stub and coated with a 10 nm layer
of gold and palladium using a Jeol JFC-2300HR High Resolution fine coater. Five images from
different areas of the tumor were captured from each tumor at x10 000 magnification.
Protein Extraction andWestern Blot Analysis
The protein expression of integrin α11 in tumors lysates and cultured tumor cell lines was
investigated. Tumor samples and cultured cell lines were lysed in buffer containing 50 mM
Tris-HCl, pH 7.4, 150 mMNaCl and 1% Triton X supplemented with one tablet of protease
inhibitor cocktail (complete EDTA-free; Roche Diagnostics GMBh, Mannheim, Germany) per
10 ml buffer. After homogenization, tumor samples were centrifuged for 10 min at 12 000 rpm
and protein concentration was measured using PierceTM BCA Protein Assay Kit (Life Technol-
ogies, Thermo Fisher Scientific, Waltham, MA., USA) according to the manufacturer’s proto-
col. For western blot analysis cell lines were grown to confluency in 6 well plates washed with
cold PBS, lysed and scraped with cell scraper on ice. Cell lysates were centifuged at 13 000 rpm
for 30 min at +4° C, and supernatant harvested. Protein lysates were loaded in XT Sample
Buffer, 4X (Bio-Rad Laboratories, Inc, Hercules, CA., USA) containing 50 mMDL-Dithiothrei-
tol (dTT) (Sigma-Aldrich, Steinheim, Germany), and run through a 10% PreciseTM Protein
Gel (Life Technologies, Thermo Fisher Scientific). The proteins were then transferred to a
nitrocellulose membrane using InvitrogenTM iBlot1 Dry Blotting System (Life Technologies,
Thermo Fisher Scientific) and an iBlot1 Transfer Stack (Life Technologies, Thermo Fisher
Scientific). After blocking in I-block (Life Technologies, Thermo Fisher Scientific) for 1 hour at
room temperature, the membranes were incubated over-night with rabbit polyclonal anti-
mouse α11 antiserum [22] 1:500 in I-block at +4°C. The anti-mouse α11 antiserum is produced
against the peptide CRREPGLDPTPKVLE from the integrin α11 cytoplasmic domain (Innova-
gen AB, Lund, Sweden) [22]. This was followed by incubation with a HRP-coupled secondary
antibody (goat anti-rabbit; AB97051, Abcam, Cambridge, UK; 1:5000 in TBS-T). The bands
were visualized by the ECL system PierceTM ECLWestern Blotting Substrate (Life Technolo-
gies, Thermo Fisher Scientific). The membrane was then re-probed with β-actin antibody
(AB8227, Abcam; 1:5000 in I-block) and HRP-coupled secondary antibody (goat anti-rabbit;
AB97051, Abcam; 1:5000 in TBS-T). Membranes were visualized using the Gel ChemiDoc sys-
tem and Quantity One 4.6.6 imaging software (Bio-Rad Laboratories, Inc, Hercules, CA.,
USA).
Picrosirius-Red and Immunofluorescence Staining
For a semi-quantitative measurement of collagen type I and III, picrosirius-red stain (Poly-
sciences inc, Warrington, FL., USA) was used. Five paraffin embedded tumor sections with a
thickness of 5μ from each group were deparaffinized, stained in picrosirius-red for one hour,
dehydrated and mounted. Five to six images from each tumor were captured with x10 magnifi-
cation (Nikon Digital Sight, Nikon Corporation, Tokyo, Japan).
For α-SMA staining, FITC-conjugated monoclonal anti-actin α-smooth muscle antibody
(F3777, dilution 1:200, Sigma Aldrich, Steinheim, Germany) was used. Five paraffin embedded
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tumor sections with a thickness of 10μ from each group were stained. Prior to staining, the sec-
tions were first deparaffinized, and then placed in citrate buffer for 25 minutes in 95°C. Non-
specific background staining was reduced by adding 0.3% hydrogen peroxide in methanol to
the sections. Five images from each tumor were captured with x20 magnification with an Axio-
scope fluorescence microscope and a digital AxiocamMRm camera (Zeiss, Oberkochen,
Germany).
To identify the amount of pixels positive for picrosirius-red staining and α-SMA, the soft-
ware Image J (National Institute of Health, Beteshda, MD., USA) was used. Individual thresh-
old values were set for each image to adjust for differences in intensity and background. For
both stainings, images were taken in an organized pattern in the tumor periphery in order to
avoid the necrotic central area.
Metastasis
To allow development of metastasis, female animals were injected with 3 x 105 4T1 cells in
their right, fifth mammary fat pad. The experiment was ended on day 21 due to animal welfare.
The lungs were fixed using approximately 1 ml of Bouin’s solution (Gurr BDH Chemicals Ltd,
Poole, UK) injected into the trachea. Then the lungs were dissected out, fixed in new Bouin’s
solution and washed in 70% ethanol before dehydration. Immediately following this procedure,
the liver and brain were harvested and fixed in formalin. All tissues were embedded in paraffin
using standard procedures, sectioned, and stained with hematoxylin and eosin (H & E). To
quantify lung metastasis, three coronal sections, 600 μm apart and covering both lungs, were
examined for each animal. The number of metastases per section was counted and total area
covered by metastases was measured (Nikon Digital Sight, Nikon Corporation, Tokyo, Japan).
Statistical Analysis
For statistical analysis, Sigmaplot 12.5 (Systat Software Inc., Chicago, IL., USA) and Graph Pad
Prism 6 (GraphPad Software, Inc., La Jolla, CA., USA) were used. Either the unpaired two-
tailed t-test or the Mann UWhitney t-test, were used to analyze statistical differences between
the two groups. For analysis of tumor growth, t-test with Welch correction was used. The mice
injected with 4T1 cells were sacrificed at either day 17 or day 18, and the tumors harvested on
the same day were tested against each other. Results were accepted as statistically different
when p< 0.05. Graph Pad Prism 6 was used to create all figures. Data is given as mean ± SD,
and number of measurements (n) refers to number of tumors unless otherwise specified.
Results
Integrin α11 Expression
Using western blotting, integrin α11 was found to be expressed in tumor lysates from both 4T1
and RM11 tumors grown in WTmice, whereas no integrin α11 was detected in the tumors
grown in α11-KO mice (Fig 1). No integrin α11 expression was detected in lysates from cul-
tured 4T1 and RM11 tumor cells (Fig 1).
Tumor Growth
The tumor volume of RM11 prostate tumors grown subcutaneously were significantly impeded
(p< 0.04 and 0.02) in tumors grown in α11-KO mice compared to tumors grown in WT mice
during their 13 day growth period, whereas 4T1 mammary tumors did not show any difference
in tumor growth between α11-KO mice and WTmice when comparing tumors that were
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harvested on the same day (17 or 18) (Fig 2). All end-point measurements in the 4T1 tumor
model are summarized at day 17 in Fig 2.
α-Smooth Muscle Actin (α-SMA) Expression
α-SMA immunofluorescent stained tumor sections were used to quantify the relative amount
of activated fibroblasts in the tumors (represented by pixels). There was no significant differ-
ence in the level of α-SMA expression in the 4T1 or the RM11 tumors grown in α11-KO mice
compared to that in WT mice (Fig 3).
Tumor Collagen Structure
In the present study collagen structure in the α11-KO versus WT tumors was compared by
measuring the collagen fibril diameters using transmission electron microsopy (TEM) analyses.
An uneven distribution of fibril diameter was found, leading to a shift towards thinner collagen
fibrils in 4T1 carcinomas grown in α11-KO mice compared to WT (Fig 4A). The average colla-
gen diameter in the 4T1 tumors grown in α11-KO mice (37.2 ± 1.5 nm) was significantly
smaller (p< 0.006) than in WTmice (50.4 ± 3.0 nm) (Fig 4B). In the RM11 tumors there was
no such difference in the collagen diameter between the tumors grown in α11-KO andWT
mice (Fig 4D). To evaluate whether the decreased collagen fibril diameter was a more general
feature in the α11-KO mice and not only tumor specific, collagen fibril diameter in dermis
Fig 1. The integrin α11 expression in 4T1 (A) and RM11 (B) cultured tumor cells and tumor lysates from
tumors in SCID integrin α11 wild type (+/+) and SCID integrin α11-deficient (-/-) mice. Positive control is a
SV40 transformed wildtype mouse embryonic fibroblast cell line (MEF).
doi:10.1371/journal.pone.0151663.g001
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from healthy male mice was evaluated. In dermis, no difference in the collagen diameter
between α11-KO and WTmice was found.
Scanning electron microscopy (SEM) did not show any difference in collagen architecture
between the α11-KO andWT neither in the 4T1 tumors nor the RM11 tumors (Fig 5).
Tumor Collagen Amount
Picrosirius-red staining was used to quantify the most abundant collagens; type I and III, in the
tumor sections. No significant difference in the amount of collagen was seen in the 4T1 and the
RM11 tumors grown in α11-KO compared to those grown in WTmice (Fig 6).
Tumor Interstitial Fluid Pressure (PIF)
Tumor PIF was determined using the wick-in-needle technique. There was no significant dif-
ference in PIF in either 4T1 or RM11 tumors grown in α11-KO versus WT mice (Fig 7).
Tumor Metastases
To evaluate whether stromal integrin α11 has an effect on metastatic potential, H & E stained
sections from the 4T1 metastatic model were used. The 4T1 breasts cancer cell line is known to
metastasize to lungs, liver, bone and brain [23]. Excessive macroscopic surface metastases were
observed in all lungs. There was no difference in the 4T1 tumor cells ability to metastasize to
the lungs in the α11-KO mice compared to the WTmice investigated at day 21 post injection
(Fig 8). Metastases were also observed in the livers. In addition, the livers were significantly
infiltrated by isles of extramedullary hematopoiesis, thereby making it difficult to quantify
these metastases. Hence, the liver metastases were not further evaluated. No metastases were
found in the brain of any of the animals at endpoint day 21.
Fig 2. The growth of 4T1 (A) and RM11 (B) tumors in SCID integrin α11 wild type (WT) and SCID integrin α11-deficient (α11-KO) mice. A total of 1 x 106 4T1
and 3 x 105 RM11 cells were injected into the mammary fat pad and subcutaneously in the mouse flank, respectively. Endpoint values in the 4T1 model
include tumors that were harvested on days 17 and 18. Mean ± SEM. * p < 0.04, ** p < 0.02.
doi:10.1371/journal.pone.0151663.g002
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Discussion
Stromal integrin α11β1 has been implicated to play a role in experimental non-small-cell lung
cancer (NSCLC) carcinogenesis [9, 10], and is expressed in human lung cancer [9, 17, 24] and
in metastasis from human malignant melanoma [16]. However, the role of integrin α11β1 in
other cancer types remains to be elucidated.
The present study showed that the primary tumor growth of RM11 prostate tumors was
reduced in α11-deficient mice compared with WTmice, however, this was not the case in 4T1
mammary tumors. Furthermore, there was a shift towards thinner collagen fibrils in the 4T1
tumors grown in α11-deficient mice. In spite of altered collagen fibrils, there were no differ-
ences in the amount of activated fibroblasts, total collagen content, collagen organization or
PIF in the tumors. In addition, the metastatic potential to the lung of 4T1 tumors was not
affected by stromal α11-deficiency.
In this study we examined the role of integrin α11 in tumor stroma. Following injection of
tumor cells in both WT and α11-KO mice, the implanted tumor cells derive their stroma from
the host animal, and hence the tumors in α11-KO mice will have stroma that is deficient in
integrin α11. Differences in tumor development can be presumed to be due to differences in
tumor stroma between the two groups since the tumor cells injected are the same. As seen in
Fig 3. Percentage of pixels positive for α-SMA in 4T1 (n = 5) and RM11 (n = 5) tumors from SCID integrin α11 wild type (WT) and SCID integrin α11-deficient
(α11-KO) mice were calculated from immunofluorescent images (A, D). No statistical differences in 4T1 (p = 0.62) or RM11 (p = 0.40) tumors were found
using unpaired two-tailed t-test. Mean ± SD. Representative images of α-SMA-staining (green) from both genotypes in 4T1 (B, C) and RM11 (E, F) tumors
are shown. Scale bars indicate 50 μm.
doi:10.1371/journal.pone.0151663.g003
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Fig 4. Collagen fibrils were analyzed using transmission electron microscopy (TEM).Collagen fibril
diameter distribution and average fibril diameter per tumor in 4T1 (n = 7 and n = 5) tumors (A, B), showed a
shift towards thinner fibrils in SCID integrin α11-deficient (α11-KO) mice. RM11 tumors (n = 4 and n = 3) (C,
D) and dermis (n = 4 and n = 3) (E, F) showed no significant differences in average collagen fibril diameter in
SCID integrin α11 wild type (WT) and SCID integrin α11-deficient (α11-KO) mice (RM11 p = 0.20, dermis
Integrin α11β1 and Tumor Growth
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Fig 1, we find that integrin α11 is expressed in tumors grown in WTmice, but not in the
tumors grown in α11-KO mice.
There are only two previous in vivo studies concerning tumor growth and stromal integrin
α11-deficiency, and they both showed a stimulatory effect of integrin α11 on tumor growth [9,
10]. First, wildtype mouse embryonic fibroblasts (MEFs) were found to have a greater stimulat-
ing effect on the growth of human NSCLC cells than MEFs lacking integrin α11 when co-
p = 0.47) using unpaired two-tailed t-test. Mean ± SD. * p < 0.006. Representative TEM images of collagen
fibrils from both genotypes in 4T1 tumors (G, H), RM11 tumors (I, J) and dermis (K, L) are shown. Scale bars
indicate 0.2 μm.
doi:10.1371/journal.pone.0151663.g004
Fig 5. A representative scanning electron micrograph of collagen in 4T1 tumors (n = 3) from SCID integrin α11 wild type (WT) (A) and SCID integrin
α11-deficient (α11-KO) (B) and RM11 tumors (n = 3) fromWT (C) and α11-KOmice (D), respectively. Scale bars indicate 1 μm.
doi:10.1371/journal.pone.0151663.g005
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injected in mice together with tumor cells [9]. Second, in a recent study by Navab et al.,
reduced tumor growth in α11-KO mice was described using subcutaneously implanted NSCLC
xenografts [10]. In addition, in an in vitro heterospheroid model, Lu et al. showed that human
lung cancer cells grown with WT fibroblasts had a higher tendency to proliferate and migrate
compared to tumor cells grown with fibroblasts deficient in integrin α11 [18]. Taken together,
these studies indicate that α11 integrin on fibroblasts interact with tumor cells and can play a
role in regulating tumor growth. Nevertheless, in the present study we only found an effect on
tumor growth in the subcutaneously implanted RM11 tumor model, and not in the orthotopi-
cally implanted 4T1 tumor model. It is not known whether these effects are tumor-type spe-
cific, or if other factors such as the location of tumor implantation, is of importance.
Integrin α11 is a collagen-binding integrin, and has previously been shown to play a role in
collagen reorganization both in vitro and in vivo [10, 14, 15]. In this study we found that the
collagen fibrils in the 4T1 tumors grown in integrin α11-deficient mice were thinner than
those in tumors grown in WTmice. However, this finding was not universal, since the RM11
tumors showed no difference in collagen fibril diameter. A recent study on wound healing also
found an increase in thinner collagen fibrils in the granulation tissue from integrin α11-defi-
cient mice [25]. Furthermore, the study demonstrated that α11-deficiency resulted in reduced
Fig 6. The total fraction of picrosirius-red staining quantified in 4T1 (n = 5) and RM11 (n = 5 and n = 3) tumors in SCID integrin α11 wild type (WT) and SCID
integrin α11-deficient (α11-KO) (A, D). No statistical differences in 4T1 (p = 0.82) or RM11 (p = 0.37) tumors were found using unpaired two-tailed t-test.
Mean ± SD. Representative images of picrosirius-red staining from both genotypes in 4T1 (B, C) and RM11 (E, F) tumors are shown. Scale bars indicate
100 μm.
doi:10.1371/journal.pone.0151663.g006
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formation of granulation tissue and impaired wound contraction [25]. As tumors can be
looked upon as “wounds that do not heal” and involve many of the same processes [26], this
could represent an interesting parallel to the present study. It is somewhat surprising that in
the current study the shift towards thinner collagen fibrils only was seen in the 4T1 model, in
which there was no effect of integrin α11 deficiency on tumor growth, whereas no alteration in
collagen fibrils was seen in the RM11 tumor model.
Activated fibroblasts play a crucial role in synthesis and remodeling of collagen in tumors
[27, 28]. We found here that the amount of activated fibroblasts, identified by the marker α-
SMA, was the same in tumors grown in α11-deficient mice when compared with WTmice.
This does not correspond to the findings in the study on NSCLC where a decrease in α-SMA
expression in α11-KO xenograft tumors was found compared to in WT xenograft tumors [10].
Moreover, reduced α-SMA expression was found in granulation tissue in integrin α11-deficient
mice compared to WTmice [25]. In addition, also two earlier studies have suggested that integ-
rin α11 stimulates fibroblast differentiation under different conditions [29, 30]. Thus, available
data suggest that integrin α11 may play a role in activation of fibroblasts, although in this study
we did not observe any difference in α-SMA expression in tumors grown in α11-deficient mice
compared to WT mice.
Regarding the amount of collagen in the tumors, there was no significant difference in the
amount of picrosirius-red staining in the 4T1 or the RM11 tumors in the present study. This
does not correspond with the recent study on NSCLC where the amount of fibrillar collagen
was reduced in xenografts in α11-KO compared to WTmice [10].
While we did not observe any difference in collagen organization in 4T1 or RM11 tumors,
neither with SEM nor with picrosirus-red staining, Navab et al [10] found that collagen had a
more non-linearized pattern in NSCLC tumors in α11-KO mice using different approaches,
namely picrosirius-red staining, second harmonic generation imaging and atomic force
Fig 7. The individual interstitial fluid pressures (PIF) in 4T1 (A) and RM11 (B) tumors in SCID integrin α11 wild type (WT) and SCID integrin α11-deficient
(α11-KO) mice. The horizontal lines indicate the mean values. No statistical differences in 4T1 (p = 0.78) or RM11 (p = 0.47) tumors were found using
unpaired two-tailed t-test.
doi:10.1371/journal.pone.0151663.g007
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Fig 8. Histomorphometric quantification of H & E -stained lungs from the 4T1 model from SCID integrin α11 wild type (WT) (n = 4) and SCID integrin
α11-deficient (α11-KO) (n = 5) mice. Average number of metastasis per section (A) and average area per section (B) is shown. The horizontal lines indicate
the mean values. No significant differences were observed (p = 0.73 and p = 0.79) using Mann UWhitney t-test and unpaired two-tailed t-test, respectively. A
representative lung with metastasis from aWTmouse is shown (C, D). Scale bar indicates 100 μm.
doi:10.1371/journal.pone.0151663.g008
Integrin α11β1 and Tumor Growth
PLOS ONE | DOI:10.1371/journal.pone.0151663 March 18, 2016 13 / 17
microscopy. It is therefore likely that the role of integrin α11 in collagen organization differs in
the NSCLC tumor model compared to the tumor models that were used in the present study.
Taken together, reduced tumor growth in α11-KO mice, has in an earlier study, been shown
to be concomitant with reduced α-SMA and altered collagen structure in the tumors [10]. The
findings in the present study, however, are different. Stromal α11-deficiency caused reduced
RM11 tumor growth, despite no differences in collagen fibril diameter, collagen amount or α-
SMA expression. In addition, there is a smaller proportion of activated fibroblasts (a-SMA
staining) and collagen in the RM11 tumors than the 4T1 tumors (Figs 3 and 6), and one could
therefore suggest that these stromal factors seem less relevant for RM11 tumor pathogenesis.
Hence, in this study, the difference in tumor growth cannot be associated to changes in fibro-
blast activation or collagen alterations, and the pathogenesis behind the reduced tumor growth
in the present study remains unknown. One can conclude, however, that the present findings
indicate that different tumors seem to show different responses to stromal integrin α11-defi-
ciency, although the mechanisms responsible are at this point not yet known.
One of the common features in the tumor microenvironment is the high interstitial fluid
pressure (PIF), which can hinder efficient delivery of cytostatic drugs across the capillary bar-
rier and into the tumor [31, 32]. Therefore, pharmacologically lowering of PIF can improve
transport of cytostatic drugs [32]. Collagen in tumors has been recognized to be one of the fac-
tors important for tumor PIF [32–34]. Furthermore, two previous studies have shown that
integrin α11 may have a role in regulating PIF in different conditions [15, 18]. It was of interest
for us, therefore, to investigate the effect of stromal α11 deficiency on tumor PIF. In this study
we did not find any difference in PIF between tumors grown in integrin α11-deficient mice
compared to WT mice, indicating that α11 may not be important for PIF regulation in these
tumors. Since collagen content is one of the factors that have been shown to be important for
PIF [32–34], and the present study did not reveal any effect of stromal integrin α11 deficiency
on amount of collagen in the tumors, an unchanged PIF was probably to be expected.
Little is known about how integrin α11 affects tumor metastasis, although there are some find-
ings that indicate that it may play a role in the metastatic process. Integrin α11 mRNA has been
found to be expressed in human metastases frommalignant melanoma and high mRNA levels of
the collagen binding integrins α1, α2 and α11 correlated with poor patient outcome [16].
In the in vivo study by Navab et al., NCI-H460SM lung carcinoma cells formed significantly
less spontaneous metastases in SCID integrin α11-deficient mice compared to SCIDWTmice
[10]. Furthermore, in a heterospheroid in vitromodel it was found that human lung cancer
cells had reduced migratory and invasive capacity when cultured together with integrin
α11-KO fibroblasts compared with WT fibroblasts [18]. Some studies have also indicated that
integrin α11 on cancer cellsmay be important in the metastatic process, such as the study by
Westcott et al where integrin α11 was among the genes highly expressed in a subpopulation of
breast cancer cells with enhanced invasiveness [35]. Furthermore, two separate tumor studies
indicate that integrin α11 RNA is upregulated during epithelial to mesenchymal transition
(EMT) [36, 37].
However, in spite of earlier findings, in the present study we found no indication that there
was a difference in lung metastases of 4T1 tumors grown in the integrin α11-deficient mice
compared to those grown in WTmice, again demonstrating that integrin α11`s role in cancer
development may vary in different tumor models.
Conclusion
The present study showed reduced tumor growth in the α11-deficient mice in the RM11
model, but no effect in the 4T1 model, only partially confirming the suggested role of integrin
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α11 in promoting tumor growth. Even though the present study demonstrated an alteration in
collagen fibril diameter in 4T1 mammary tumors in the α11-deficient mice, it did not confirm
previously shown alterations in collagen amount and organization, or in α-SMA expression.
These discrepancies may be due to differences in tumor model, tumor type, location and
aggressiveness of the tumor type. Our findings clearly show that further investigations regard-
ing the role of integrin α11β1 in different tumor types are needed.
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